Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The internet-related business delivered higher revenue and profit, driven by growing demand for IT engineers against a backdrop of DX, steady performance in the SES business and the impact of the subsidiary acquired in the previous fiscal year. The telecommunications business saw lower revenue and profit due to intensifying competition. The dispensing pharmacy and related businesses delivered higher revenue and profit, driven by an increase in prescription volumes and efforts to reduce selling, general and administrative expenses.
No applicable matters ("There are no applicable matters")
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥4,374 million (YoY +9.2%) |
| Operating profit | ¥102 million |
| Ordinary income | ¥90 million |
| Profit attributable to owners of the parent | ¥17 million |
| Net income per share | ¥3.81 |
| Equity ratio | End of the current fiscal period 42.9 / End of previous period 41.5 |
| Total assets | ¥7,026 million |
| Net assets | ¥3,011 million |
| Cash flows from operating activities | ¥272,016 thousand |
| Cash flows from investing activities | ¥-32,499 thousand |
| Cash flows from financing activities | ¥-313,944 thousand |
| Cash and cash equivalents at end of period | ¥2,070,745 thousand |
| Full-year earnings forecast | Net Sales ¥8,928 million (YoY +7.2%) / Operating profit ¥159 million / Ordinary income ¥128 million / Net income ¥7 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Internet-Related Business ¥820 million (YoY +57.4%), Telecommunications Business ¥102 million (YoY -6.0%), Dispensing pharmacies and related businesses ¥3,465 million (YoY +2.1%) |
| Segment profit | Internet-Related Business ¥41 million (YoY +65.1%), Telecommunications Business ¥8 million (YoY -15.4%), Dispensing pharmacies and related businesses ¥318 million (YoY +39.7%) |
| Depreciation and amortization | ¥66,396 thousand |
| Disclosure regarding the going concern assumption | No applicable matters ("There are no applicable matters") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | Added: 0 companies; excluded: 0 companies |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (no applicable participants) |
| Issued Shares at Period-End | 4,677,720 |
| Treasury Shares at Period-End | 49,060 |
| Factors Behind Changes in Business Performance | The internet-related business delivered higher revenue and profit, driven by growing demand for IT engineers against a backdrop of DX, steady performance in the SES business and the impact of the subsidiary acquired in the previous fiscal year. The telecommunications business saw lower revenue and profit due to intensifying competition. The dispensing pharmacy and related businesses delivered higher revenue and profit, driven by an increase in prescription volumes and efforts to reduce selling, general and administrative expenses. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The system engineering services business performed steadily against a backdrop of strong DX demand, and was also supported by the impact of a subsidiary acquired in the previous fiscal year. The dispensing pharmacy business delivered higher revenue and profit, driven by an increase in prescription volumes and efforts to reduce selling, general and administrative expenses. In contrast, the telecommunications business saw lower revenue and profit due to intensifying competition.